Search PubMed⌕ Search

Biomedical subjects

R H Carter

Publications and source records attributed to R H Carter.

32 records · Page 2Linked to original sources
PubMed1992

CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.

Lymphocytes must proliferate and differentiate in response to low concentrations of a vast array of antigens. The requirements of broad specificity and sensitivity conflict because the former is met by low-affinity antigen receptors, which precludes achieving the latter with high-affinity receptors. Coligation of the membrane protein CD19 with the antigen receptor of B lymphocytes decreased the threshold for antigen receptor-dependent stimulation by two orders of magnitude. B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. The B cell resolves its dilemma by having an accessory protein that enables activation when few antigen receptors are occupied.

Animals↗
PubMed1991

The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex.

We have investigated the mechanism by which the membrane protein complex of the B lymphocyte that contains CD19 and CR2 activates phospholipase C (PLC) to induce a rise in [CA2+]i. The CD19 complex resembled the membrane IgM complex in that three protein tyrosine kinase inhibitors suppressed increases in [Ca2+]i and inositol bisphosphate and inositol triphosphate generation. However, the activation of PLC by the CD19 complex could be distinguished from that by the membrane IgM complex by slower kinetics of generation of inositol phosphates, resistance to inhibition by activators of protein kinase C, and different pattern of tyrosine-phosphorylated cellular substrates. Western blot analysis of lysates from cells stimulated by the CD19 complex demonstrated a single new phosphotyrosine-containing protein of 85 kDa, whereas multiple other phosphotyrosine-containing proteins were present in cells activated by the mIgM complex. In particular, PLC-gamma 1, which is a substrate for the protein tyrosine kinase activated by the mIgM complex, was not tyrosine-phosphorylated in cells stimulated by the CD19 complex. Cross-linking the two complexes together caused a synergistic increase in [CA2+]i which was neither suppressed by activation of protein kinase C nor associated with increased tyrosine-phosphorylation of PLC, characteristic of the CD19 pathway. Therefore, the B cell has two signal transduction complexes, associated with membrane IgM and CD19, that activate PLC by different mechanisms and that can synergistically interact to enhance this function by the CD19 pathway.

Antigens, CD↗
PubMed1991

Tyrosine phosphorylation of phospholipase C induced by membrane immunoglobulin in B lymphocytes.

Ligation of membrane IgM on B lymphocytes causes activation of a protein-tyrosine kinase(s) (PTK) and of phospholipase C (PLC). To determine whether these are elements of a common signal-transduction pathway, the effect of three PTK inhibitors on the rise in intracellular free Ca2+ concentration [( Ca2+]i) in human B-lymphoblastoid cell lines was assessed. Tyrphostin completely suppressed the increase in [Ca2+]i and the generation of inositol phosphates induced by ligation of membrane immunoglobulin (mIg) M. Herbimycin and genistein reduced by 30% and 50%, respectively, the rise in [Ca2+]i caused by optimal ligation of mIgM, and they abolished it in cells activated by suboptimal ligation of mIgM. Tyrphostin had no effect on the capacity of aluminum fluoride to increase [Ca2+]i. To determine whether a function of PTK is the phosphorylation of PLC, immunoprecipitates obtained with anti-phosphotyrosine from detergent lysates of B-lymphoblastoid cells were assayed for PLC activity. Ligation of mIgM increased immunoprecipitable PLC activity 2-fold by 90 sec and 4-fold by 30 min. Specific immunoprecipitation and Western blot analysis identified tyrosine phosphorylation of the gamma 1 isoform of PLC after 60 sec of stimulation. Activation of PLC in B cells by mIgM requires PTK function and is associated with tyrosine phosphorylation of PLC-gamma 1, suggesting a mechanism of PLC activation similar to that described for certain receptor PTKs.

Aluminum↗
PubMed1991

Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19.

The complement system augments the humoral immune response, possibly by a mechanism that involves the B lymphocyte membrane receptor, CR2, which binds the C3dg fragment of C3 and triggers several B cell responses in vitro. The present study demonstrates that CR2 associates with a complex of membrane proteins that may mediate signal transduction by ligated CR2. Monoclonal antibodies to CR2 immunoprecipitated from digitonin lysates of Raji B lymphoblastoid cells a membrane complex containing CR2, approximately equimolar amounts of CD19, which is a member of the immunoglobulin superfamily, and three unidentified components: p130, p50, and p20. The complex, which was immunoprecipitated also with anti-CD19, could be dissociated by Nonidet P-40, accounting for its absence in previous studies of CR2. Expression of recombinant CR2 and CD19 in K562 erythroleukemia cells led to formation of a complex that contained not only these two proteins but also p130, p50, and p20, and another component, p14. These unidentified components of the CR2/CD19 complex coimmunoprecipitated with CD19 and not with CR2 from singly transfected cells, indicating primary association with the former. CD19 replicated the capacity of CR2 to interact synergistically with mIgM for increasing free intracellular Ca2+, suggesting that the complex mediates this function of CR2. Therefore, CR2 associates directly with CD19 to become a ligand-binding subunit of a pre-existing signal transduction complex of the B cell that may be representative of a family of membrane protein complexes. This interaction between the complement and immune systems differs from that between immunoglobulin and Clq by involving membrane rather than plasma proteins, and by having complement involved in the afferent phase of the immune response.

Antigens, CD↗
PubMed1989

Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2.

Complement receptor type 2 (CR2;CD21), a member of the superfamily of proteins containing short consensus repeats (SCRs), is the B cell receptor for both the gp350/220 envelope protein of Epstein-Barr virus (EBV), and for the C3dg protein of complement. By analysis of CR2 deletion mutants and chimeras formed with CR1 (CD35) we determined that of the 15 SCRs in CR2, the NH2-terminal two SCRs are necessary and sufficient to bind both gp350/220 and C3dg with affinities equivalent to those of the wild-type receptor. The epitope for OKB-7, a mAb that blocks binding of both EBV and C3dg and shares with these ligands B cell-activating capabilities, also requires both SCR-1 and SCR-2, whereas mAbs lacking these functions bind to other SCRs. Thus, EBV, a polyclonal activator of B cells, has selected a site that is proximate or identical to the natural ligand binding site in CR2, perhaps reflecting the relative immutability of that site as well as its signal transducing function.

Animals↗
PubMed1989

Polymeric C3dg primes human B lymphocytes for proliferation induced by anti-IgM.

Polymeric C3dg (pC3dg), having an average m.w. of approximately 400,000 and saturating complement receptor type 2 (CR2) on B lymphoblastoid cells at 1 micrograms/ml, was preincubated with tonsillar B cells for 24 h, after which anti-IgM was added and proliferation assessed by thymidine incorporation. Preculture of B cells with 0.01 to 1.0 micrograms/ml of polymerized C3dg (pC3dg) caused a dose-dependent enhancement of proliferation and accelerated entry into S phase after addition of anti-IgM. The continued presence of pC3dg during stimulation by anti-IgM was not required. pC3dg alone did not induce proliferation and preculture of B cells with C3dg monomer had no effect on the subsequent response to anti-IgM. The priming effect of pC3dg required at least 6 h and was greatest after 24 h of preculture. Preincubation with pC3dg did not lower the concentration of anti-IgM necessary for induction of proliferation, but did enhance proliferation at all concentrations above this threshold. Augmented proliferation occurred only in B cells of higher density in Percoll gradients, and neither T cells nor monocytes were required. Thus, independent interaction of CR2 with its natural ligand primes the B cell for subsequent stimulation through the Ag receptor, an effect that might synergize with the previously described CR2 function of lowering the threshold for B cell activation when crosslinked to membrane IgM.

Antibodies, Anti-Idiotypic↗
PubMed1988

Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes.

We sought biochemical evidence for a role of C receptors types 1 (CR1) and 2 (CR2) in B cell activation. A flow cytometer was used to measure the fluorescence of tonsillar cells that had been loaded with the calcium-dependent indicator indo-1, and cells were stimulated by cross-linking cell-bound DA4.4 anti-IgM, Yz-1 anti-CR1 or HB5 anti-CR2 with goat anti-mouse IgG. There was a direct dose-response relationship between the proportion of cells having increased cytoplasmic free calcium concentration (Cai) after addition of second antibody and the amount of cell-bound Fab' DA4.4. In contrast, no rise in Cai was observed after cross-linking bound Yz-1 or HB5. To determine whether CR1 or CR2 could modify the increase in Cai induced by cross-linking membrane IgM, Cai was monitored after addition of second antibody to cells bearing combinations of either Yz-1 or HB5 with a limited amount of DA4.4. The combination of Yz-1 with DA4.4 yielded little or no further increase in the percentage of cells responding to cross-linking with elevated Cai compared with DA4.4 alone. However, the combination of HB5 with limited DA4.4 synergistically enhanced this response, resulting in stimulation that was equivalent to that obtained with optimal concentrations of DA4.4. The synergistic effect of CR2 was also observed with avidin as the cross-linking reagent for bound biotinylated HB5 and DA4.4, occurred in the presence of EGTA, and did not require T cells. Studies of the proliferation of B cell-enriched PBMC demonstrated that, whereas HB5 coupled to Sepharose alone induced little or no DNA synthesis, the combination of HB5 with limited DA4.4 on Sepharose induced a dose-related synergistic increase in the incorporation of [3H]thymidine.

B-Lymphocytes↗
PubMed1987

Total IgE and allergen-specific IgE assays: guidelines for the provision of a laboratory service.

The Analytical Methods Working Party of the Association of Clinical Biochemists (ACB) established this Task Force to consider the measurement of total serum IgE and specific IgE. The aims were to give general guidance on available methods of assay; to survey commercial kits and 'in-house' methods; to investigate performance based on external Quality Assessment and independent evaluation, and to advise on criteria laboratories should consider before setting up IgE and specific IgE assays.

Allergens↗
PubMed1983

Regulation of the immune response to tumor antigens. IX. In vitro Lyt-1+2- cell proliferative responses to cellbound or subcellular tumor antigen.

We investigated the cellular basis of immune reactivity to the S1509a fibrosarcoma in tumor-immune A/J mice. In a Winn assay, immune Lyt-1+2- T cells are capable of retarding S1509a tumor growth in naive A/J mice. In vitro proliferation to S1509a is also mediated by tumor-immune Lyt-1+2- T cells. This response is specific to the immunizing tumor and appears 5 to 7 days after reexposure to the tumor in vivo. Proliferation also requires the presence of a population of adherent cells. In fact, adherent peritoneal exudate cells pulsed with tumor membrane fragments derived from S1509a cells can stimulate proliferation. Proliferation is blocked by the addition of anti-I-Ak monoclonal antibody to the culture medium without complement or by treatment of the responder population with anti-I-Ak and complement. In vitro responsiveness is also inhibited by the presence of tumor-specific suppressor T cells in vivo. These observations suggest in vitro proliferation may provide a potential means of defining tumor antigens and cell-surface structures involved in tumor immunity.

Animals↗
PubMed1977

Quality control in the microbiological serum folate assay.

Low values obtained in the microbiological assay of serum folate are often due to the presence of antibiotics in the test serum. The assay has been modified to permit consistent recognition of the presence and extent of such contamination. Other assay variables have been investigated and a quality control system devised which rapidly identifies the presence of inconsistencies in any one assay batch. The system further allows for the reporting of some clinically useful results from an imperfect assay batch thus reducing the necessity for reassay of some test sera.

Anti-Bacterial Agents↗